Insights from natural infection-derived immunity to cholera instruct vaccine efforts

Clinical and Vaccine Immunology

Volumn 19, Issue 11, 2012, Pages 1707-1711

  Pasetti, Marcela F ^a   Levine, Myron M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA VACCINE; MORCVAX; SHANCHOL; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANTIBODY BLOOD LEVEL; B LYMPHOCYTE; BACTERIAL IMMUNITY; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CHOLERA; DRUG EFFICACY; DRUG SAFETY; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); T LYMPHOCYTE; VIBRIO CHOLERAE;

EID: 84868246212     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00543-12     Document Type: Note

References (52)

1. Alam MM, et al. 2011. Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera. Clin. Vaccine Immunol. 18:844-850.
2. Ali M, Emch M, Park JK, Yunus M, Clemens J. 2011. Natural cholera infection-derived immunity in an endemic setting. J. Infect. Dis. 204:912-918.
3. Ali M, et al. 2005. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 366:44-49. (Pubitemid 40956529)
4. Arifuzzaman M, et al. 2012. Antigen-specific memory T cell responses after vaccination with an oral killed cholera vaccine in Bangladeshi children and comparison to responses in patients with naturally acquired cholera. Clin. Vaccine Immunol. 19:1304-1311.
5. Berkowska MA, et al. 2011. Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways. Blood 118:2150-2158.
6. Calain P, et al. 2004. Can oral cholera vaccination play a role in controlling a cholera outbreak? Vaccine 22:2444-2451. (Pubitemid 38757343)
7. Charles RC, Ryan ET. 2011. Cholera in the 21st century. Curr. Opin. Infect. Dis. 24:472-477.
8. Clemens J, Shin S, Sur D, Nair GB, Holmgren J. 2011. New-generation vaccines against cholera. Nat. Rev. Gastroenterol. Hepatol. 8:701-710.
9. Clemens JD, et al. 1990. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 335:270-273. (Pubitemid 20047723)
10. Clemens JD, et al. 1991. Biotype as determinant of natural immunising effect of cholera. Lancet 337:883-884.
11. Enserink M. 2010. Infectious diseases. Haiti's outbreak is latest in cholera's new global assault. Science 330:738-739.
12. Garcia L, et al. 2005. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers. Infect. Immun. 73:3018-3024. (Pubitemid 40570371)
13. Glass RI, et al. 1985. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J. Infect. Dis. 151:236-242. (Pubitemid 15162711)
14. Harris AM, et al. 2009. Antigen-specific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh. Infect. Immun. 77:3850-3856.
15. Harris JB, et al. 2010. Cholera's western front. Lancet 376:1961-1965.
16. Harris JB, et al. 2008. Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh. PLoS Negl. Trop. Dis. 2:e221. doi:10.1371/journal.pntd.0000221. (Pubitemid 352002926)
17. Harris JB, LaRocque RC, Qadri F, Ryan ET, Calderwood SB. 2012. Cholera. Lancet 379:2466-2476.
18. Jayasekera CR, et al. 2008. Cholera toxin-specific memory B cell responses are induced in patients with dehydrating diarrhea caused by Vibrio cholerae O1. J. Infect. Dis. 198:1055-1061.
19. Johnson RA, et al. 2012. Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera. Clin. Vaccine Immunol. 19:1712-1721.
20. Kuchta A, et al. 2011. Vibrio cholerae O1 infection induces proinflammatory CD4+ T-cell responses in blood and intestinal mucosa of infected humans. Clin. Vaccine Immunol. 18:1371-1377.
21. Leung DT, Chowdhury F, Calderwood SB, Qadri F, Ryan ET. 2012. Immune responses to cholera in children. Expert. Rev. Anti. Infect. Ther. 10:435-444.
22. Leung DT, et al. 2012. Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh. Clin. Vaccine Immunol. 19:690-698.
23. Leung DT, et al. 2011. Comparison of memory B cell, antibody-secreting cell, and plasma antibody responses in young children, older children, and adults with infection caused by Vibrio cholerae O1 El Tor Ogawa in Bangladesh. Clin. Vaccine Immunol. 18:1317-1325.
24. Levine MM. 2006. Enteric infections and the vaccines to counter them: future directions. Vaccine 24:3865-3873.
25. Levine MM, et al. 1981. Duration of infection-derived immunity to cholera. J. Infect. Dis. 143:818-820. (Pubitemid 11062231)
26. Levine MM, et al. 1988. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet ii:467-470.
27. Levine MM, et al. 1979. Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. Trans. R. Soc. Trop. Med. Hyg. 73:3-9. (Pubitemid 9097253)
28. Mahalanabis D, et al. 2009. Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response. Vaccine 27:4850-4856.
29. Mosley WH, Ahmad S, Benenson AS, Ahmed A. 1968. The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients. Bull. World Health Organ. 38:777-785.
30. Mosley WH, Benenson AS, Barui R. 1968. A serological survey for cholera antibodies in rural east Pakistan. 1. The distribution of antibody in the control population of a cholera-vaccine field-trial area and the relation of antibody titre to the pattern of endemic cholera. Bull. World Health Organ. 38:327-334.
31. Mosley WH, McCormack WM, Ahmed A, Chowdhury AK, Barui RK. 1969. Report of the 1966-67 cholera vaccine field trial in rural East Pakistan. 2. Results of the serological surveys in the study population-the relationship of case rate to antibody titre and an estimate of the inapparent infection rate with Vibrio cholerae. Bull. World Health Organ. 40:187-197.
32. Passwell JH, et al. 2010. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. Vaccine 28:2231-2235.
33. Patel SM, et al. 2012. Memory B cell responses to Vibrio cholerae O1 lipopolysaccharide are associated with protection against infection from household contacts of patients with cholera in Bangladesh. Clin. Vaccine Immunol. 19:842-848.
34. Plotkin SA, Gilbert PB. 2012. Nomenclature for immune correlates of protection after vaccination. Clin. Infect. Dis. 54:1615-1617.
35. Qadri F, et al. 1998. Enteric infections in an endemic area induce a circulating antibody-secreting cell response with homing potentials to both mucosal and systemic tissues. J. Infect. Dis. 177:1594-1599. (Pubitemid 28243584)
36. Qadri F, et al. 2003. Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: comparison to antibodysecreting cell responses and other immunological markers. Infect. Immun. 71:4808-4814. (Pubitemid 36919952)
37. Qadri F, et al. 1997. Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1. Infect. Immun. 65:3571-3576. (Pubitemid 27398109)
38. Ramirez K, et al. 2012. Intranasal vaccination with an adjuvanted Norwalk virus-like particle vaccine elicits antigen-specific B memory responses in human adult volunteers. Clin. Immunol. 144:98-108.
39. Richie EE, et al. 2000. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 18:2399-2410.
40. Rollenhagen JE, et al. 2009. Transcutaneous immunization with a synthetic hexasaccharide-protein conjugate induces anti-Vibrio cholerae lipopolysaccharide responses in mice. Vaccine 27:4917-4922.
41. Shin OS, et al. 2011. LPLUNC1 modulates innate immune responses to Vibrio cholerae. J. Infect. Dis. 204:1349-1357.
42. Shin S, Desai SN, Sah BK, Clemens JD. 2011. Oral vaccines against cholera. Clin. Infect. Dis. 52:1343-1349.
43. Simon JK, et al. 2011. Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates. Clin. Immunol. 139:185-192.
44. Simon JK, et al. 2009. Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated Shigella flexneri 2a vaccine candidates. Vaccine 27:565-572.
45. Simon R, Levine MM. 1 April 2012, posting date. Glycoconjugate vaccine strategies for protection against invasive Salmonella infections. Hum. Vaccin. Immunother. [Epub ahead of print.] http://dx.doi.org/10.4161/hv.19158.
46. Suntharasamai P, et al. 1992. Clinical and bacteriological studies of El Tor cholera after ingestion of known inocula in Thai volunteers. Vaccine 10: 502-505.
47. Sur D, et al. 2011. Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. PLoS Negl. Trop. Dis. 5:e1289. doi:10.1371/journal.pntd.0001289.
48. Tarique AA, et al. 2012. Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice. Clin. Vaccine Immunol. 19:594-602.
49. Uddin T, et al. 2011. Mucosal immunologic responses in cholera patients in Bangladesh. Clin. Vaccine Immunol. 18:506-512.
50. Wahid R, et al. 2011. Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans. Clin. Immunol. 138:187-200.
51. Wahid R, Simon R, Zafar SJ, Levine MM, Sztein MB. 2012. Live oral typhoid vaccine Ty21a induces cross-reactive humoral immune responses against Salmonella enterica serovar Paratyphi A and S. Paratyphi B in humans. Clin. Vaccine Immunol. 19:825-834.
52. WHO. 2010. Cholera vaccines: WHO position paper. Wkly. Epidemiol. Rec. 85:117-128.